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Background: Post-dilatation (PD) has been advocated as intra-procedural treatment
of paravalvular regurgitation (PVR) immediately following transcatheter aortic valve
replacement (TAVR). The purpose of this study is to determine if the use of three-
dimensional (3DE) annular sizing affects the rate of PD following TAVR.
Methods: Intra-procedural transesophageal echocardiograms were performed on 276
pts with severe aortic stenosis: 150 pts used only traditional 2DE annulus measure-
ments for valve sizing and 126 pts used 3DE annulus measurements for valve sizing.
Sagittal plane annulus diameter was measured from long-axis views of the aorta by
2DE. Annular area and perimeters are measured by 3DE and average diameters
calculated. Cover indexes, a measure of valve oversizing, were calculated using
transcatheter heart valve nominal diameter and 2DE or 3DE measured or calculated
annular diameters as well as THV area and 3DE annular area.
Results: Table 1 shows the comparison of 2DE only and 3DE cohorts; there was no
signiﬁcant difference between these groups in baseline aortic valve area (AVA) or
sagittal annular diameter. Sagittal plane annular cover index by 3DE was larger, but
not statistically different from 2DE measurements. There was a signiﬁcant reduction in
the PD rate for the 3DE cohort (27% vs 45%, p¼0.027) with no difference in post-
TAVR EOA (p¼0.30), indexed EOA (p ¼ 0.58) or PVR (p¼0.29).
Conclusions: Despite similar annular diameters, pts using 3DE-guided sizing had
a signiﬁcant decrease in the rate of PD with no difference in post-TAVR valve area or
PVR. 3DE cover index algorithms for sizing may reduce the rate of PD without
signiﬁcantly affecting hemodynamic outcomes.Table 1. Comparison of patient with 2DE vs 3DE annular measurement
2DE only
N=154
3DE
N=129 P Value
Age 86.17.3 83.78.3 0.012
% Female 44% 57% 0.027
BSA 1.790.25 1.770.23 0.70
Baseline AVA 0.630.20 0.680.24 0.09
Sagittal Annulus 22.71.8 22.72.1 0.96
Cover Index (Diameter) 8.94.4 (Sag) 9.64.6 0.16
(Area) 7.95.4 vs Sag <0.0001
(Perimeter) 6.64.9 vs Sag <0.001
vs Area <0.001
Cover Index (Area) 15.18.6
PD Frequency 68/150 (45%) 34/92 (27%) 0.027
Mean EOA (cm2) 1.990.36 1.940.40 0.296
Mean EOAi (cm2/m2) 1.100.21 1.100.20 0.576
Mean PVR* 1.320.61 1.240.56 0.290
*PVR is treated as a continuous variable using the following grading scheme: 1¼none/trace,
2¼mild, 3¼moderate, 4¼severe
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“Paradoxical” low ﬂow low gradient severe aortic valve stenosis – an entity with
limited improvement following transcatheter aortic valve implantation
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Background: "Paradoxical" Low ﬂow, low gradient severe aortic valve stenosis
(PLF-LG-AS) is characterized by reduced stroke volume despite preserved EF. If
managed conservatively this entity of AS is associated with poor prognosis. Our
observational single center study aimed to investigate the outcome of these patients
after transcatheter aortic valve implantation (TAVI).
Methods: Based on pre-procedural echo data, 141 patients with severe AS (AVA 
0.6 cm2/m2) who underwent TAVI at our institution were retrospectively divided into
3 groups: 1.) Paradoxical low gradient aortic valve stenosis (PLG-AS, EF  50%,
mean aortic valve gradient <40 mmHg; n ¼ 38), 2.) Classical low gradient aortic
valve stenosis (CLG-AS, EF < 50%, mean aortic valve gradient < 40 mmHg; n ¼ 19)
and 3.) High gradient aortic valve stenosis (HG-AS, EF < or  50%, mean aortic
valve gradient  40 mmHg; n ¼ 84). A sub-investigation of the PLG-AS group with
respect to stroke volume (SV or > 35 ml/m2) was performed (PLF-LG-AS: SV35
ml/m2, n¼30).
Results: Patients with PLF-LG-AS were found to have more pronounced concentric
left ventricular remodeling as deﬁned by relative wall thickness (60.615.3%)
compared to patients with HG-AS or CLG-AS: (5213%, 409% respectively;
p<0.001). Improvement in exercise capacity, which was assessed by a 6 minute
walktest at baseline and 6-12 month after TAVI, was worst in the PLF-LG-AS group
(improvement PLF-LG-AS: -0.6112.8m, CLG-AS: 6772m, HG-AS: 11289m,
intergroup p¼0.008). PLF-LG-AS was a signiﬁcant predictor of mortality at one year
in univariate analysis (HR: 2.6, p¼0.019, CI [95 %]: 1.2-5.5).
Conclusions: Patients with PLF-LG-AS may represent a subgroup with worse clinical
outcome after TAVI.
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Background: Post-dilatation (PD) can treat paravalvular regurgitation (PVR)
following transcatheter aortic valve replacement (TAVR). We studied the effect of PD
on hemodynamic outcome.
Methods: Intra-procedural TEE was performed on 276 TAVR pts; 102 pts had PD.
Measured parameters included: prosthesis-patient mismatch (PPM) [effective oriﬁce
area (EOA) < 0.85cm2/mm2]; cover index (CI) using nominal THV measurements
(diameter, perimeter or area) and two-dimensional echo (2DE) sagittal annulus or
three-dimensional echo (3DE) annulus perimeter or area; and TAVR performance
index (PI) as a measure of valve expansion (EOA/3DE annular area).
Results: PD patients were more often male, had signiﬁcantly larger BSA, and no
difference in indexed baseline or post-TAVR indexed EOA (Table I). Despite PD, the
PI was signiﬁcantly lower (p ¼ 0.045) suggesting valve under-deployment. PVR was
statistically greater in the PD patients (p<0.001) but on average remained less than
mild. PD patients had a signiﬁcantly lower prevalence of PPM (p¼0.025). The CI by
2DE and 3DE were signiﬁcantly different in the 2 groups. By ROC analysis the CI
cutoffs to predict  mild residual PVR in the No PD pts were: 7.5% for 2DE sagittal
annulus, 5.3% for 3DE perimeter and 12.1% for 3DE area (AUC 0.62-0.69, sensitivity
70-74%, speciﬁcity 50%). By ROC analysis the CI cutoffs to predict  mild residual
PVR in the PD pts were: 7.5% for 2DE sagittal annulus, 2.9% for 3DE perimeter and
10.5% for 3DE area (AUC 0.66-0.67, sensitivity 70%, speciﬁcity 50-57%).
Conclusions: Compared to pts without PD, pts requiring PD post-TAVR had valve
under-deployment, more residual PVR, but signiﬁcantly less PPM. To prevent  mild
PVR a 3DE perimeter CI of >5.3% (without PD) or >2.9% (with PD) and 3DE area
CI of >12.1% (without PD) or >10.5% (with PD). This sizing algorithm should be
tested in a larger patient population.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
Table 1. Comparison of PD versus no PD patient groups.
No PD (N=174)
PD
(N=102) p Value
BSA 1.750.23 1.850.24 <0.0001
Sex (male) 68/174 69/102 <0.0001
Sagittal Annulus 22.301.96 23.321.62 <0.0001
3D Perimeter 72.67.1 76.36.0 0.004
3D Area 410.981.2 451.268.4 0.007
Baseline EOA
indexed(cm2/m2)
0.360.11 0.380.15 0.30
Post TAVR EOA
indexed(cm2/m2)
1.100.22 1.120.019 0.517
Performance Index
3DE (Area)
0.470.07 (n¼87) 0.440.06 (n¼33) 0.046
Mean PVR* 1.130.39 1.550.75 <0.0001
Prosthesis-Patient
Mismatch
15/159 (9.4%) 5/98
(5%)
0.025
Cover Index 2DE (%) 10.34.4 7.73.8 <0.0001
Cover Index 3DE
Perimeter (%)
7.54.4 4.65.0 0.005
Cover Index 3DE
Area (%)
16.77.9 11.79.2 0.007
*PVR is treated as a continuous variable using the following grading scheme: 1¼none/trace,
2¼mild, 3¼moderate, 4¼severe
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Difference of Short Term Outcome in Low, Intermediate and High risk Patient in
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Background: Short term outcome of TAVI in intermediate and low risk patient is not
well known. We performed a cross sectional study to investigate short term mortality
and major cardiovascular event (MACE) in low and intermediate risk patients, and
compared to those in high risk patients.
Methods: Consecutive 125 patients who received TAVI were included in the study.
High, intermediate and low risk for surgical aortic valve replacement (S-AVR) was
deﬁned as STS score was 10 or higher, 4-9.99 and less than 4, respectively. MACE was
deﬁned as death, stroke, myocardial infarction, unplanned open chest or peripheral
vascular repair/intervention, acute kidney injury and lethal bleeding according to the
VARC deﬁnition. Odds ratios (ORs) of in hospital mortality andMACE in intermediate
and low risk patients compared to high risk patients were calculated with multivariate
logistic regression analysis adjusted for patient background.
Results: 35, 70 and 20 patients were included in high, intermediate and low risk
group. Mortality was observed in 3 (8.6%), 2 (2.9%) and 0 (0%) patients and mortality
rate in each risk group was same or lower than bottom level of STS score deﬁned in
each risk stratiﬁcation (10%, 4% and 0%). MACE was observed in 14 (40.0%), 12
(17.1%) and 2 (10.0%) patients. ORs of mortality in intermediate and low risk group
were 0.53 (95%CI: 0.02-12.3, p ¼ 0.70) and <0.55 (95%CI: 0.00-0.00, p < 0.23).
ORs of MACE were 0.27 (95% CI: 0.10-0.74, p ¼ 0.011) and 0.27 (95% CI: 0.05-
1.54, p ¼ 0.14). No signiﬁcant difference in mortality and MACE between interme-
diate and low risk group (p ¼ 1.00 and p ¼ 0.73, respectively).
Conclusions: Compared to surgical risk, mortality rate was lower especially in high
and intermediate risk group in TAVI. Compared to high risk patients, intermediate and
low risk patients showed lower risk for in hospital mortality and MACE although
difference did not reach statistical signiﬁcance due to lack of sample size. Intermediate
and low risk patients showed similar short term outcome after TAVI. Result of the
study indicated a possibility that TAVI is effective especially for intermediate risk
patient for S-AVR.
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Background: The aim of this study was to assess the role of transcatheter aortic valve
implantation (TAVI) compared with medical treatment (MT) and surgical aortic valve
replacement (SAVR) in patients presenting with low-ﬂow, low-gradient (LFLG)
severe aortic stenosis (AS).
Methods: Between 2006 and 2012, 142 patients with LFLG severe AS (indexed
aortic valve area [AVAi] 0.6cm2.m-2, ejection fraction [EF] <50% and mean
gradient [MG] <40mmHg) and a complete pre-TAVI right and left heart catheteri-
zation underwent treatment allocation to MT (n¼28) SAVR (n¼41) or TAVI (n¼73).
Results: Baseline characteristics were similar among patients allocated to MT and
TAVI, whereas patients allocated to SAVR were younger (MT 82.05.2 vs SAVR
75.75.6 vs TAVI 82.24.8 years, p<0.0001) and were at lower predicted surgical risk
(Logistic EuroSCORE MT 39.114.1 vs SAVR 20.713.6 vs TAVI 35.715.2%).
Pre-procedural invasive hemodynamic indices were similar among MT and TAVI
patients, whereas patients allocated to SAVR had a higher MG (p¼0.03) and EF
(p¼0.008) and lower pulmonary artery (PA) systolic (p<0.0001) pressures. OverallMG
was 26.48.4 mmHg, mean AVAi was 0.330.12, mean systemic vascular resistance
was 2071.9701.0 dyne.s.cm-2,mean PApressurewas 36.710.8mmHg andmean EF
was 33.08.8 %. All-cause mortality at 30-days was similar among SAVR (4.9%) and
TAVI (5.5%) patients, but was non-signiﬁcantly higher among MT patients (17.9%,
p¼0.08). Unadjusted rates of all-cause mortality at 12 months were signiﬁcantly lower
for SAVR (17.1%) and TAVI (17.8%) as comparedwithMT (42.9%, p¼0.02). Adjusted
hazard ratios for death were 0.39 (95% conﬁdence interval: 0.16 to 0.94) for SAVR
compared withMT and 0.35 (95% conﬁdence interval: 0.17 to 0.70) for TAVI compared
with MT. Medical treatment (p¼0.02) and pulmonary hypertension (p¼0.03) were
signiﬁcantly associated with all-cause mortality at 12 months on multivariate analysis.
Conclusions: Among patients with low-ﬂow, low-gradient severe AS, SAVR and
TAVI improved survival compared with MT. Clinical outcomes of TAVI and SAVR
appeared similar among appropriately selected patients with LFLG severe AS.
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Background: There is a trend for use of advanced adjunctive technology to support
trans-catheter aortic valve implantation. It is not clear whether this approach is
superior to a minimalist approach.
Methods: We assessed in-hospital MACE, 30-day and 1 year clinical outcomes
among patients undergoing TAVI employing a less intensive assessment and
performance protocol, using registry data from two UK TAVI centres. Mortality
tracking was reported as of December 2012.
Results: Within the study cohort (n¼384) mean age was 81.47.0 years and 46.3%
were male. Logistic EuroSCORE was 19.211.6. Mean peak aortic valve gradient
and aortic valve area were 79.725.2mmHg and 0.620.20cm2 respectively. Aortic
annular size was assessed by transthoracic echo (TTE; 73.4%), transoesophageal echo
(TOE; 24.5%) and multislice computerised tomography (MSCT; 0.5%). Mean aortic
annular diameter was 23.12.4mm. Pre-procedural iliofemoral assessment was by
invasive contrast angiography (99.5%) or MSCT (0.5%). Procedures were performed
under local anaesthetic alone (39.1%), local anaesthetic and anaesthetic sedation
(46.0%), or general anaesthesia (14.9%). Device implantation was predominantly with
the CoreValve self-expanding prosthesis (87.7%) and via the femoral approach
(90.7%). Device implantation employed contrast aortography in all cases with
supportive TTE (85%), TOE (3.4%), or no additional imaging (11.6%). Procedural
success was 96.1%. Procedural complications included death (0.8%) and valve-in-
valve implantation (3.1%). Overall in-hospital MACE was 6.0%. Aortic regurgitation
grade2 was seen in 12.5%. Mortality rates were in-hospital 3.5%, 30-day 5.5% and
one-year 15.2%.
Conclusions: Excellent TAVI clinical outcomes can be achieved despite limited use
of computerised tomography, transoesophageal echocardiography and general
anaesthesia.acts/POSTER/Aortic Valve Disease and Treatment B217
